SEC Form 4	
------------	--

Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ROBINS CHAD M			2. Issuer Name and Ticker or Trading Symbol <u>Adaptive Biotechnologies Corp</u> [ADPT]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)																
(Last) (First) (Middle) C/O ADAPTIVE BIOTECHNOLOGIES				3. Date of Earliest Transaction (Month/Day/Year) 03/19/2020								CEO and Chairman														
CORPORATION 1551 EASTLAKE AVE E STE 200																										
	4.1										6. Individual or Joint/Group Filing (Check Applicable Line)															
2										Form f		filed by More tha		•		ng										
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																										
Date	Year) if any		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Disposed Of	Acquired (A) or (D) (Instr. 3, 4 and		d 5) Securities Beneficially Owned Fol			Form: Di (D) or Inc	irect direct 4)	Indired Benefi Owner	neficial nership										
					Code	v	Amount	(A) or (D)	Price		Transaction				(msu.	+)										
03/19/202	20				M ⁽¹⁾		11,120	A	\$0.3	3	1,889,3	00	D													
03/19/202	20				S ⁽¹⁾		11,120	D	\$22.3	<mark>3</mark> (2)	1,878,1	80	D													
03/20/202	20				M ⁽¹⁾		5,560	Α	\$0. 3	3	1,883,7	40	D													
Common Stock 03/20/202		20			S ⁽¹⁾		3,700	D	\$22.3	7 ⁽³⁾	1,880,040) D													
Common Stock 03/20/202		20		S ⁽¹⁾		973	D	\$23.5	5 ⁽⁴⁾	1,879,067		D														
Common Stock 03/20/20					S ⁽¹⁾		887	D	\$24.3	8 (5)	1,878,180		D													
											500,000		I(e)		By HSR 2014 Mother's Trust U/T/A dated June 17, 2014											
											350,00	00	I(6))	2017 Trust Desc u/a/d Nove	Trust for endants mber										
											Owned															
eemed 4	I.		5. Nur		6. Da	te Exei	rcisable and	7. Title	and Am		8. Price of			10.		11. Nature										
í c	Code (I		Secur Acqui (A) or Dispo of (D)	ities red sed (Instr.				of Securities Underlying Derivative Secu (Instr. 3 and 4)		-	Derivative der Security Se (Instr. 5) Ow Fol Re Tra (Instr. 5)		rative Own rities Forn ficially Dire ed or In wing (I) (I orted saction(s)		ership of Indirec Beneficia t (D) Ownersh direct (Instr. 4)											
c	Code	v	(A) ((D)	Date Exerc	cisable	Expiration Date	Title	or Nun of	ıber																
N	M ⁽¹⁾			11,120	(7)		(7)		(7)		(7)		(7)		(7)		12/20/2021	Common Stock 11,2		200	\$0.00 7		702,160 I			
N	M ⁽¹⁾			5,560		(7)	12/20/2021			560	\$0.00	69	6,600	D												
	2 Non-Deriv 2. Transactic Date (Month/Day/ 03/19/20 03/20/20 04/20	Image: Provide state st	Adapti a. Jace of 03/19/20 3. Date of 03/19/20 4. If Amer 2 2 2. Transaction Date (Month/Day/Vear) 2. Transaction Date (Month/Day/Vear) 03/19/2020 03/20/2020 <	e Adaptive B 3. Date of Earlie 3. Date of Earlie 03/19/2020 4. If Amendment 2 2 2 2 2 2 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 03/19/2020 03/20/2020 2 03/20/2020 3 4 7 7 7 7 8 2	Adaptive Biotect a. daptive Biotect 3. Date of Earliest Trans 03/19/2020 4. If Amendment, Date 2 beta 2 Control 2. Transaction Date (Month/Day/Year) 03/19/2020 03/19/2020 03/20/2020	Adaptive Biotechnol Adaptive Biotechnol Biotechnol Biotechnol Biotechnol Biotechnol Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2"	Adaptive Biotechnologie Image: Section of Contract of Contra	A daptive Biotechnologies Corp [A daptive Biotechnologies Corp	Adaptive Biotechnologies Corp [ADPT Determed Biotechnologies Corp [ADPT Date of Earliest Transaction Date frany Month/Day/Vear) 03/19/2020 A. Deemed Biotechnologies (Top [ADPT) A. Beemed Biotechnologies (Top [ADPT) 03/20/2020 A. Deemed Biotechnologies (Top [ADPT) A. Beemed Biotechnologies (Top [ADPT) A. Beemed Biotechnologies (Top [ADPT) 03/20/2020 A. Deemed Biotechnologies (Top [ADPT) A. Beemed Biotechnologies (Top [ADPT) A. Beemed Biotechnologies (Top [ADPT) Oddeemed Biotechnologies (Top [ADPT) O	Adaptive Biotechnologies Corp [ADPT] a. Date of Earliest Transaction (Month/Day/Year) 03/19/2020 c. Non-Derivative Securities Acquired (Month/Day/Year) 2 a. Security and the securities acquired (Month/Day/Year) 2 a. Securities acquired (Month/Day/Year) 3 a. Securities acquired (Month/Day/Year) 3 a. Securities acquired (Month/Day/Year) 03/19/2020 a. Securities acquired (Month/Day/Year) b. Securities acquired (Month/Day/Year) 03/20/2020 a. Securities acquired (Month/Day/Year) b. Securities acquired (Month/Day/Year) b. Securities acquired (Month/Day/Year) 21 - Derivative Securities acquired (Month/Day/Year) S. Number (Month/Day/Year) b. Date Securities acquired (Month/Day/Year) a. Securities acquired (Month/Day/Year) 21 - Derivative Securities acquired (Month/Day/Year) S. Number (Month/Day/Year) b. Date Securities acquired (Month/Day/Year)	Adaptive Biotechnologies Corp [ADPT] (ch a. Date of Earliest Transaction (Month/Day/Year) (ch 3. Date of Earliest Transaction (Month/Day/Year) (ch 4. If Amendment, Date of Original Filed (Month/Day/Year) (ch 2 (Month/Day/Year) (ch 3. Transaction Date (Month/Day/Year) (ch (ch 03/19/2020 (Month/Day/Year) (ch (ch 03/19/2020 (Month/Day/Year) (ch (ch (ch) or 03/19/2020 (Month/Day/Year) S(1) 11,120 D \$22,3(2) 03/20/2020 (Month/Day/Year) S(1) 3,700 D \$22,3(2) 03/20/2020 (S(1) S(1) 3,700 D \$22,3(2) 03/20/2020 (S(1) S(1) S(1) <t< td=""><td>$\begin{array}{ c c c c c c c c c c c c c c c c c c c$</td><td>$\frac{\operatorname{Adaptive Biotechnologies Corp. [ADPT]}{\operatorname{Biotechnologies Corp. [ADPT]}} = \left(\begin{array}{cccccccccccccccccccccccccccccccccccc$</td><td>$\begin{array}{ c c c c c c } \hline Adaptive Biotechnologies Corp [ADPT] \\ \hline Adaptive Biotec$</td><td>Adaptive Biotechnologies Corp [ADPT] (Check all appicable) Call of the content of</td><td>$\begin{array}{c c c c c c c c c c c c c c c c c c c$</td></t<>	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	$ \frac{\operatorname{Adaptive Biotechnologies Corp. [ADPT]}{\operatorname{Biotechnologies Corp. [ADPT]}} = \left(\begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{ c c c c c c } \hline Adaptive Biotechnologies Corp [ADPT] \\ \hline Adaptive Biotec$	Adaptive Biotechnologies Corp [ADPT] (Check all appicable) Call of the content of	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $										

1. These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$22.04 to 22.59, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$22.03 to 22.99, inclusive.

4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$23.06 to 23.91, inclusive.

5. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$24.00 to 24.97, inclusive.

6. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

7. The options are fully vested and exercisable.

Remarks:

<u>/s/ Chad M. Robins by Eric</u> <u>Billings, Attorney-in-Fact</u>

03/23/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.